Document is current
Any future updates will be listed below
-
Authors
Zijlker, Lisanne P.
Chen, Henry
Spillane, Andrew J.
Gonzalez, Maria
Pennington, Thomas E.
Menzies, Alexander M.
Lo, Serigne N.
Ferguson, Peter
Rawson, Robert
Colebatch, Andrew J.
Stretch, Jonathan R.
Thompson, John F.
Ch’ng, Sydney
Nieweg, Omgo
Shannon, Kerwin F.
Long, Georgina V.
Scolyer, Richard A.
Saw, Robyn P. M.
van Akkooi, Alexander C. J.
-
Funding
Funding for this research was provided by:
Stichting de Drie Lichten
National Health and Medical Research Council (2022/GNT2018514)
University of Sydney
- License Information
-
More Information
Article History
Received: 7 November 2023
Accepted: 25 March 2024
First Online: 18 May 2024
Disclosure
: Alexander M. Menzies has served on an advisory board for BMS, MSD, Novartis, Roche, Pierre-Fabre, and QBiotics. John F. Thompson has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK, and Provectus Biopharmaceuticals Inc, and travel and conference support from GSK, Provectus Inc, and Novartis. Richard A. Scolyer has received fees for professional services from MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline. Robyn P. M. Sawhas received honoraria for advisory board participation from MSD, Novartis, and Qbiotics, and speaking honoraria from BMS and Novartis. Robert V. Rawson has received honoraria for speaking and advisory board participation from Merck Sharp & Dohme. Georgina V. Long is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, PHMR Ltd, Pierre Fabre, Provectus, Qbiotics, and Regeneron. Alexander C. J. van Akkooi declares advisory board and consultancy honoraria at Amgen, Bristol-Myers Squibb, MSD-Merck, Merck-Pfizer, Neracare, Novartis, Pierre Fabre, Sanofi, and Sirius Medical, 4SC, and research grants from Amgen and Merck-Pfizer. The remaining authors have no conflicts of interest.
